Table 2.
Characteristics of the Participants in Our Study for Positron Emission Tomography/Computed Tomography
| Diagnostic Criteria | IPF (n = 20) | Non-IPF (n = 63) |
||
|---|---|---|---|---|
| Idiopathic NSIP (n = 15) | CTD (n = 28) | IPAF (n = 20) | ||
| Male sex, n (%) | 19 (95.0) | 8 (53.3) | 10 (35.7) | 10 (50.0) |
| Age (yr), mean (range) | 66.0 (58–79) | 58.1 (37–71) | 55.8 (34–68) | 56.8 (37–80) |
| Drugs, n (%) | ||||
| Nintedanib | 2 (10) | 1 (6.7) | 1 (3.6) | 1 (5) |
| Pirfenidone | 16 (80) | 12 (80) | 24 (85.7) | 16 (80) |
| Imatinib | 0 | 1 (6.7) | 0 | 1 (5) |
| FAPI SUVmean, mean (range) | 2.5 (2.3–2.8) | 2.3 (2.2–2.5) | 2.5 (2.1–3.3) | 2.5 (2.1–2.8) |
| FAPI SUV total (g/ml·cm3), mean (range) | 1,010.3 (83.2–2,393.6) | 375.0 (14.8–1,200.2) | 468.5 (8.8–2,044.4) | 468.8 (2.4–1,445.3) |
| KL-6 (U/ml), mean (range) | 1,391.7 (480–4,949) | 1,425.3 (369–4,561) | 1,942.8 (408–5,162) | 1,556.8 (448–4,192) |
| Baseline FVC (% predicted), mean (range) | 80.0 (54.0–106.8) | 78.9 (40.3–109.7) | 68.8 (32.6–103.4) | 71.9 (50.0–98.8) |
| Baseline DlCO (% predicted), mean (range) | 37.6 (17.0–58.3) | 55.2 (24.3–79.6) | 47.2 (30.6–68.8) | 48.3 (26.1–73.6) |
Definition of abbreviations: CTD = connective tissue disease; IPAF = interstitial pneumonia with autoimmune features; IPF = idiopathic pulmonary fibrosis; KL-6 = Krebs von den lungen-6; NSIP = nonspecific interstitial pneumonitis; SUV = standard uptake value.